Seminars in Oncology
Volume 34 , Pages S35-S39 , December 2007

Forodesine Treatment and Post-Transplant Graft-Versus-Host Disease in Two Patients With Acute Leukemia: Facilitation of Graft-Versus-Leukemia Effect?

  • Lia Gore

      Affiliations

    • Section of Hematology/Oncology/BMT, Department of Pediatrics, University of Colorado School of Medicine and The Children’s Hospital, Denver, CO.
    • Corresponding Author InformationAddress reprint requests to Lia Gore, MD, FAAP, UCHSC at Fitzsimons, Mail Stop 8302, PO Box 6511, Aurora, CO 80045
    • ,
  • Mattias Stelljes

      Affiliations

    • Department of Medicine/Hematology and Oncology, University of Muenster, Muenster, Germany.
    • ,
  • Ralph Quinones

      Affiliations

    • Section of Hematology/Oncology/BMT, Department of Pediatrics, University of Colorado School of Medicine and The Children’s Hospital, Denver, CO.

References 

  1. Furman RR, Gore L, Ravandi F, et al. Forodesine IV (BCX-1777) is clinically active in relapsed/refractory T-cell leukemia: Results of a phase II study (interim report). Blood. 2006;108(suppl 1):524a;(abstr 1851)
  2. Furman RR, Gandhi V, Bennett JC, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood. 2004;104(suppl 1):750a;(abstr 2743)
  3. Furman RR, Iosava G, Isola L, et al. Forodesine (Fodosine™), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (phase II study). Blood. 2005;106(suppl 1):259a;(abstr 881)
  4. Nachman J, Siebel N, Sather H, et al. Outcome for adolescent and young adults 16-21 years of age (AYA) with ALL treated on the Children’s Cancer Group (CCG) 1961 study. Blood. 2004;104(suppl 1):196a;(abstr 683)
  5. Bantia S, Kilpatrick JM. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Discov Devel. 2004;7:243–247
  6. Viegas TX, Omura GA, Stoltz RR, et al. Pharmacokinetics and pharmacodynamics of Peldesine (BCX-34), on activation and proliferation of normal human lymphoid cells. J Clin Pharmacol. 2000;40:410–420
  7. Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001;1:1199–1210
  8. Sullivan KM. Graft-versus-host disease. In:  Thomas ED editors. Hematopoietic Cell Transplantation. Ed 2. Boston, MA: Blackwell Science; 1999;p. 515–536
  9. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–1826
  10. Socie G. Current issues in allogeneic stem cell transplantation. Hematology. 2005;10(suppl 1):63;(abstr)
  11. Zeng D, Lan F, Hoffman P, et al. Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation. 2004;77:S9–S11
  12. Noble A, Leggat JA, Inderberg EM. CD8+ immunoregulatory cells in the graft-versus-host reaction: CD8 T cells activate dendritic cells to secrete interleukin-12/interleukin-18 and induce T helper 1 autoantibody. Immunology. 2003;109:476–486
  13. Bantia S, Miller PJ, Parker CD, et al. Comparison of in vivo efficacy of BCX-1777 and cyclosporine in xenogeneic graft-vs.-host disease: The role of the dGTP in antiproliferative action of BCX-1777. Int Immunopharmacol. 2002;2:913–923

PII: S0093-7754(07)00224-2

doi: 10.1053/j.seminoncol.2007.11.005

Seminars in Oncology
Volume 34 , Pages S35-S39 , December 2007

Article Tools

* Image Usage & Resolution